HYAL4-V1/Chondroitinase (Chase) Drives Gemcitabine Resistance and Predicts Chemotherapy Failure in Patients with Bladder Cancer.
Sarrah L HasanaliDaley S MoreraRonny R RacineMartin HennigSantu GhoshLuis E LopezMarie C HupeDiogo O EscuderoJiaojiao WangHuabin ZhuSemih SarcanIjeoma AzihMichael ZhouAndre R JordanMartha K TerrisMarkus A KuczykAxel S MerseburgerVinata B LokeshwarPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
V1/Chase drives gemcitabine resistance and potentially predicts gemcitabine + cisplatin failure. CDA inhibition resensitizes V1-expressing tumors to gemcitabine. Because several chemotherapy regimens include gemcitabine, our study could have broad significance.